Relapsing Multiple Sclerosis Therapeutics
1. Aubagio patent expiration
Treatment: Treatment of patients with relapsing forms of multiple sclerosis; Treatment of patients with relapsing forms of multiple sclerosis while managing the risk of teriflunomide and rosuvastatin interaction...
AUBAGIO's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5679709 | SANOFI AVENTIS US | Medicaments to combat autoimmune diseases |
Oct, 2014
(11 years ago) | |
| US5459163 | SANOFI AVENTIS US | Medicament to combat autoimmune diseases |
Oct, 2012
(13 years ago) | |
| US9186346 | SANOFI AVENTIS US | Methods for reducing the risk of an adverse teriflunomide and rosuvastatin interaction in multiple sclerosis patients |
Feb, 2034
(8 years from now) | |
| US6794410 | SANOFI AVENTIS US | Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4′-trifluoromethylphenyl)-amide for treating multiple sclerosis |
Sep, 2026
(8 months from now) | |
| US8802735 | SANOFI AVENTIS US | (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluormethylphenyl)-amide tablet formulations with improved stability |
Sep, 2030
(4 years from now) | |
|
US8802735 (Pediatric) | SANOFI AVENTIS US | (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluormethylphenyl)-amide tablet formulations with improved stability |
Mar, 2031
(5 years from now) | |
|
US6794410 (Pediatric) | SANOFI AVENTIS US | Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4′-trifluoromethylphenyl)-amide for treating multiple sclerosis |
Mar, 2027
(1 year, 2 months from now) | |
|
US9186346 (Pediatric) | SANOFI AVENTIS US | Methods for reducing the risk of an adverse teriflunomide and rosuvastatin interaction in multiple sclerosis patients |
Aug, 2034
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 12, 2017 |
| M(M-61) | Apr 30, 2024 |
| Pediatric Exclusivity(PED) | Oct 30, 2024 |
Drugs and Companies using TERIFLUNOMIDE ingredient
NCE-1 date: 31 October, 2023
Market Authorisation Date: 12 September, 2012
Dosage: TABLET
How can I launch a generic of AUBAGIO before it's drug patent expiration?
More Information on Dosage
AUBAGIO family patents
2. Gilenya patent expiration
Treatment: Treatment of autoimmune disease; Treatment of relapsing remitting multiple sclerosis by determining varicella zoster virus (vzv) status and vaccinating prior to commencing treatment; Treatment of mult...
GILENYA's oppositions filed in EPO
GILENYA IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5604229 | NOVARTIS | 2-amino-1,3-propanediol compound and immunosuppressant |
Feb, 2019
(6 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6004565 | NOVARTIS | Compositions and methods of using compositions with accelerated lymphocyte homing immunosuppressive properties |
Sep, 2017
(8 years ago) | |
|
US5604229 (Pediatric) | NOVARTIS | 2-amino-1,3-propanediol compound and immunosuppressant |
Aug, 2019
(6 years ago) | |
| US5604229 | NOVARTIS | 2-amino-1,3-propanediol compound and immunosuppressant |
Feb, 2014
(11 years ago) | |
| US10543179 | NOVARTIS | Dosage regimen of an S1P receptor modulator |
Dec, 2027
(1 year, 11 months from now) | |
| US9592208 | NOVARTIS | Formulations comprising 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol |
Mar, 2032
(6 years from now) | |
| US9187405 | NOVARTIS | S1P receptor modulators for treating relasping-remitting multiple sclerosis |
Jun, 2027
(1 year, 5 months from now) | |
| US8324283 | NOVARTIS | Solid pharmaceutical compositions comprising a SIP receptor agonist and a sugar alcohol |
Mar, 2026
(2 months from now) | |
|
US8324283 (Pediatric) | NOVARTIS | Solid pharmaceutical compositions comprising a SIP receptor agonist and a sugar alcohol |
Sep, 2026
(8 months from now) | |
|
US9187405 (Pediatric) | NOVARTIS | S1P receptor modulators for treating relasping-remitting multiple sclerosis |
Dec, 2027
(1 year, 11 months from now) | |
|
US9592208 (Pediatric) | NOVARTIS | Formulations comprising 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol |
Sep, 2032
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-106) | Jul 20, 2014 |
| New Chemical Entity Exclusivity(NCE) | Sep 21, 2015 |
| New Patient Population(NPP) | May 11, 2021 |
| New Strength(NS) | May 11, 2021 |
| Pediatric Exclusivity(PED) | Nov 11, 2021 |
Drugs and Companies using FINGOLIMOD HYDROCHLORIDE ingredient
NCE-1 date: 11 November, 2020
Market Authorisation Date: 11 May, 2018
Dosage: CAPSULE
How can I launch a generic of GILENYA before it's drug patent expiration?
More Information on Dosage
GILENYA family patents
3. Ponvory patent
expiration
Treatment: Treatment of relapsing forms of multiple sclerosis (ms), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults using a dose titratio...
PONVORY's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9062014 | VANDA PHARMS INC | Crystalline forms of (R)-5-[3-chloro-4-(2,3-dihydroxy-propoxy)-benz[Z]ylidene]-2-([Z]-propylimino)-3-0-tolyl-thiazolidin-4-one |
May, 2032
(6 years from now) | |
| USRE43728 | VANDA PHARMS INC | Thiazolidin-4-one derivatives |
Nov, 2029
(3 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12336980 | VANDA PHARMS INC | Dosing regimen for a selective S1P1 receptor agonist |
Dec, 2035
(9 years from now) | |
| US9000018 | VANDA PHARMS INC | Thiazolidin-4-one-derivatives |
Nov, 2024
(1 year, 1 month ago) | |
| US8273779 | VANDA PHARMS INC | Thiazolidin 4-one derivatives |
Dec, 2025
(23 days ago) | |
| US10220023 | VANDA PHARMS INC | Dosing regimen for a selective S1P1 receptor agonist |
Dec, 2035
(9 years from now) | |
| US11951097 | VANDA PHARMS INC | Methods of treating multiple sclerosis |
Oct, 2042
(16 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 18, 2026 |
Drugs and Companies using PONESIMOD ingredient
NCE-1 date: 18 March, 2025
Market Authorisation Date: 18 March, 2021
Dosage: TABLET
More Information on Dosage
PONVORY family patents
4. Tecfidera patent expiration
Treatment: Method of treating multiple sclerosis; Method of treating an autoimmune disease selected from autoimmune polyarthritis and multiple sclerosis but not treating psoriatic arthritis; Method of treating r...
TECFIDERA's oppositions filed in EPO
TECFIDERA IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7320999 | BIOGEN INC | Dimethyl fumarate for the treatment of multiple sclerosis |
May, 2020
(5 years ago) | |
| US8759393 | BIOGEN INC | Utilization of dialkylfumarates |
Jul, 2018
(7 years ago) | |
| US8524773 | BIOGEN INC | Utilization of dialkylfumarates |
Apr, 2018
(7 years ago) | |
| US7803840 | BIOGEN INC | Utilization of dialkylfumarates |
Apr, 2018
(7 years ago) | |
| US7619001 | BIOGEN INC | Utilization of dialkylfumarates |
Apr, 2018
(7 years ago) | |
| US6509376 | BIOGEN INC | Utilization of dialkyfumarates |
Oct, 2019
(6 years ago) | |
| US8399514 | BIOGEN INC | Treatment for multiple sclerosis |
Feb, 2028
(2 years from now) | |
| US10555993 | BIOGEN INC | Dimethyl fumarate and vaccination regimens |
Mar, 2035
(9 years from now) | |
| US10959972 | BIOGEN INC | Methods of treating multiple sclerosis |
Nov, 2035
(9 years from now) | |
| US10391160 | BIOGEN INC | Dimethyl fumarate and vaccination regimens |
Mar, 2035
(9 years from now) | |
| US11129806 | BIOGEN INC | Methods of treating multiple sclerosis |
Nov, 2035
(9 years from now) | |
| US10994003 | BIOGEN INC | Dimethyl fumarate and vaccination regimens |
Mar, 2035
(9 years from now) | |
| US11007166 | BIOGEN INC | Methods of treating multiple sclerosis |
Nov, 2035
(9 years from now) | |
| US11007167 | BIOGEN INC | Methods of treating multiple sclerosis |
Nov, 2035
(9 years from now) | |
| US11246850 | BIOGEN INC | Methods of treating multiple sclerosis |
Nov, 2035
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 27, 2018 |
| M(M-260) | Feb 05, 2023 |
Drugs and Companies using DIMETHYL FUMARATE ingredient
NCE-1 date: 27 March, 2017
Market Authorisation Date: 27 March, 2013
Dosage: CAPSULE, DELAYED RELEASE
How can I launch a generic of TECFIDERA before it's drug patent expiration?
More Information on Dosage
TECFIDERA family patents
5. Vumerity patent expiration
Treatment: Method of treating multiple sclerosis
VUMERITY's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10080733 | BIOGEN INC | Prodrugs of fumarates and their use in treating various diseases |
Sep, 2033
(7 years from now) | |
| US8669281 | BIOGEN INC | Prodrugs of fumarates and their use in treating various diseases |
Oct, 2033
(7 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9090558 | BIOGEN INC | Prodrugs of fumarates and their use in treating various diseases |
Sep, 2033
(7 years from now) | |
Drugs and Companies using DIROXIMEL FUMARATE ingredient
Market Authorisation Date: 29 October, 2019
Dosage: CAPSULE, DELAYED RELEASE
How can I launch a generic of VUMERITY before it's drug patent expiration?
More Information on Dosage
VUMERITY family patents
6. Zeposia patent expiration
Treatment: Treatment of moderately to severely active ulcerative colitis (uc) in adults; Treatment of relapsing forms of multiple sclerosis (ms), to include clinically isolated syndrome, relapsing-remitting dise...
ZEPOSIA's oppositions filed in EPO
Can you believe ZEPOSIA received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US11680050 | BRISTOL | Crystalline forms of ozanimod and ozanimod hydrochloride, and processes for preparation thereof |
Sep, 2038
(12 years from now) | |
| US8481573 | BRISTOL | Modulators of sphingosine phosphate receptors |
Mar, 2033
(7 years from now) | |
| US8796318 | BRISTOL | Modulators of sphingosine phosphate receptors |
May, 2029
(3 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10239846 | BRISTOL | Selective sphingosine 1 phosphate receptor modulators and methods of chiral synthesis |
Nov, 2030
(4 years from now) | |
| US9382217 | BRISTOL | Modulators of sphingosine phosphate receptors |
May, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-860) | May 27, 2024 |
| New Chemical Entity Exclusivity(NCE) | Mar 25, 2025 |
| M(M-309) | Aug 30, 2027 |
Drugs and Companies using OZANIMOD HYDROCHLORIDE ingredient
NCE-1 date: 25 March, 2024
Market Authorisation Date: 25 March, 2020
Dosage: CAPSULE
More Information on Dosage
ZEPOSIA family patents